X4 Pharmaceuticals (XFOR) Wells Fargo 21st Annual Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Wells Fargo 21st Annual Healthcare Conference summary
10 Sep, 2026Program updates and trial design
Lead program mavorixafor is in phase III (4WARD trial) for chronic neutropenia, targeting increased neutrophil counts and reduced infections.
Enrollment target was reduced to 126 patients after FDA agreement, aiming for completion by year-end.
Powering for infection and ANC endpoints remains strong at 88% and 93%, respectively, with conservative assumptions maintained.
Operational improvements, including a CRO change, have accelerated enrollment and increased U.S. patient participation.
The trial enrolls a sick population with low ANC and frequent infections, aligning with FDA guidance.
Safety, efficacy, and future studies
Over 500 patients have received mavorixafor, and the FDA considers the safety database sufficient for review.
The trial is designed for a one-third reduction in infection rate, which is seen as commercially meaningful.
No stratification by disease subtype; about 50% of patients are idiopathic, and G-CSF use is randomized but not capped.
Dose selection is based on robust pharmacokinetic and phase II data, supporting efficacy and safety.
A new open-label G-CSF titration study is planned to guide reduction or discontinuation of G-CSF in patients.
Market opportunity and commercialization
Estimated 15,000 U.S. patients with chronic neutropenia and recurrent infections, mostly managed in community hematology practices.
Patients are accessible through hematologists, and the market is expected to shift with the introduction of an oral alternative to G-CSF.
Pricing is anticipated in the $200,000–$300,000 range annually, below the WHIM indication price.
No advanced competitors beyond G-CSF are currently identified.
U.S. commercialization will be direct, with a sales force of 50–60 reps and 5–6 regional managers; ex-U.S. options depend on partner decisions.
Latest events from X4 Pharmaceuticals
- 4WARD data expected in early 2028; 4STEPS will test G-CSF dose reduction.XFOR
Jefferies Global Healthcare Conference - 4WARD enrollment targets year-end 2026, with topline data expected in Q1 2028.XFOR
Stifel 2026 Healthcare Conference 2026 - 4WARD enrollment is targeted for year-end 2026; top-line results are expected in Q1 2028.XFOR
3rd Annual Guggenheim Healthcare Innovation Conference - Higher product sales and 4WARD progress accompany debt refinancing and runway into Q1 2029.XFOR
Q3 2026 - Mavorixafor’s PCN opportunity pairs a ~15,000-patient base with Q1 2028 readouts.XFOR
Investor Day 2026 - 4WARD topline data are expected in H1 2028, backed by Phase 2 evidence of ANC gains and reduced G-CSF use.XFOR
Corporate presentation - Q2 2026 revenue was $8.8M, net loss improved, and cash runway extends into 2029.XFOR
Q2 2026 - Q2 net income hit $90.8M on $105M PRV sale and XOLREMDI U.S. launch.XFOR
Q2 2024 - Mavorixafor durably increased ANC and showed good tolerability in chronic neutropenia Phase 2.XFOR
Study Update